Literature DB >> 30280060

An Overview of Our Current Understanding of Diabetic Macular Ischemia (DMI).

Muhammad Usman1.   

Abstract

Diabetic macular ischemia (DMI) is a troublesome complication of diabetes mellitus. The pathogenesis, progression, consequences, and treatment options for this disease are still poorly understood. However, it is believed that this complication is associated with several risk factors like poor glycemic control and high blood pressure. Two factors have been identified in the pathogenesis of the disease that play pivotal roles in disease development and progression. One of these factors includes extensive damage to the microvasculature of the retina. This includes narrowing of the vascular lumen and extensive damage to the endothelial cells, pericytes and the extracellular matrix. The second factor includes extensive damage to the neurosensory layer of the retina. DMI is always associated with other complications of diabetic retinopathy like retinal edema, so it is very difficult to find an isolated case of DMI. Moreover, the condition is also very rare making it very difficult to study and diagnose. However, a number of diagnostic tests like optical coherence tomography (OCT), fluorescence angiography (FA), and perimetry can be used as tools for the early detection of DMI. Since this disease damages the retina, loss of vision is an inevitable consequence that can progressively worsen over time. Also, DMI has been implicated as a risk factor for retinal edema and progressive diabetic retinopathy. Until now, no defined treatment protocol has been devised. The only available treatments focus on the management of risk factors (hyperglycemia and hypertension). Still, many aspects of DMI remain poorly studied and understood. This review paper aims to add to our current understanding of diabetic macular ischemia (DMI).

Entities:  

Keywords:  diabetes; diabetic macular ischemia; dmi; retinopathy

Year:  2018        PMID: 30280060      PMCID: PMC6166915          DOI: 10.7759/cureus.3064

Source DB:  PubMed          Journal:  Cureus        ISSN: 2168-8184


  32 in total

1.  Quantitative analysis of diabetic macular ischemia using optical coherence tomography.

Authors:  Dawn A Sim; Pearse A Keane; Simon Fung; Michael Karampelas; Srinivas R Sadda; Marcus Fruttiger; Praveen J Patel; Adnan Tufail; Catherine A Egan
Journal:  Invest Ophthalmol Vis Sci       Date:  2014-01-21       Impact factor: 4.799

2.  The evolution and natural history of diabetic retinopathy.

Authors:  E M Kohner
Journal:  Int Ophthalmol Clin       Date:  1978

3.  Antiplatelet effects of prostacyclin and nitric oxide in patients with type I diabetes and ischemic or edematous retinopathy.

Authors:  J P De La Cruz; A Moreno; A Guerrero; F S de La Cuesta
Journal:  Platelets       Date:  2001-06       Impact factor: 3.862

4.  Plasminogen activators promote excitotoxicity-induced retinal damage.

Authors:  Raghuveer S Mali; Mei Cheng; Shravan K Chintala
Journal:  FASEB J       Date:  2005-08       Impact factor: 5.191

5.  Retinal ischemia in diabetic retinopathy.

Authors:  G H Bresnick; G De Venecia; F L Myers; J A Harris; M D Davis
Journal:  Arch Ophthalmol       Date:  1975-12

6.  Foveal avascular zone in diabetic retinopathy: quantitative vs qualitative assessment.

Authors:  J Conrath; R Giorgi; D Raccah; B Ridings
Journal:  Eye (Lond)       Date:  2005-03       Impact factor: 3.775

Review 7.  Microvascular basement membranes in diabetes mellitus.

Authors:  Effie C Tsilibary
Journal:  J Pathol       Date:  2003-07       Impact factor: 7.996

8.  Association of Diabetic Macular Nonperfusion With Outer Retinal Disruption on Optical Coherence Tomography.

Authors:  Fabio Scarinci; Lee M Jampol; Robert A Linsenmeier; Amani A Fawzi
Journal:  JAMA Ophthalmol       Date:  2015-09       Impact factor: 7.389

9.  Foveal avascular zone in diabetes mellitus.

Authors:  A M Mansour; A Schachat; G Bodiford; R Haymond
Journal:  Retina       Date:  1993       Impact factor: 4.256

10.  Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group.

Authors: 
Journal:  Lancet       Date:  1998-09-12       Impact factor: 79.321

View more
  10 in total

1.  Sema3A Antibody BI-X Prevents Cell Permeability and Cytoskeletal Collapse in HRMECs and Increases Tip Cell Density in Mouse Oxygen-Induced Retinopathy.

Authors:  Nina Zippel; Cynthia Hess Kenny; Helen Wu; Michel Garneau; Rachel Kroe-Barrett; Priyanka Gupta; Sarah Low; Remko A Bakker; Leo Thomas
Journal:  Transl Vis Sci Technol       Date:  2022-06-01       Impact factor: 3.048

2.  Visual Field Outcomes in the Tube Versus Trabeculectomy Study.

Authors:  Swarup S Swaminathan; Alessandro A Jammal; Helen L Kornmann; Philip P Chen; William J Feuer; Felipe A Medeiros; Steven J Gedde
Journal:  Ophthalmology       Date:  2020-03-04       Impact factor: 14.277

3.  Factors based on optical coherence tomography correlated with vision impairment in diabetic patients.

Authors:  Hiroaki Endo; Satoru Kase; Hikari Tanaka; Mitsuo Takahashi; Satoshi Katsuta; Yasuo Suzuki; Minako Fujii; Susumu Ishida; Manabu Kase
Journal:  Sci Rep       Date:  2021-02-04       Impact factor: 4.379

4.  HORNBILL: a phase I/IIa trial examining the safety, tolerability and early response of BI 764524 in patients with diabetic retinopathy and diabetic macular ischaemia-rationale, study design and protocol.

Authors:  Victor Chong; Quan Dong Nguyen; Yasir Sepah; Andrea Giani; Elizabeth Pearce
Journal:  Trials       Date:  2022-08-17       Impact factor: 2.728

5.  Living Without a Diagnosis: A Patient's Perspective on Diabetic Macular Ischemia.

Authors:  Jacqueline D Humphreys; Sobha Sivaprasad
Journal:  Ophthalmol Ther       Date:  2022-07-12

6.  Optical coherence tomography angiography analysis of changes in the foveal avascular zone in eyes with diabetic macular edema treated with intravitreal anti-vascular endothelial growth factor.

Authors:  Albert John Bromeo; Patricia Grulla-Quilendrino; Ruth Camille Antolin; Emil Joshua John Salcedo; Cheryl A Arcinue; Ralph Anthony De Jesus; Amadeo Veloso
Journal:  Int J Retina Vitreous       Date:  2022-08-26

Review 7.  Diabetic Retinopathy May Covariate With Stroke in Diabetes Mellitus.

Authors:  Meetali Kalani; Pranaykumar Shinde
Journal:  Cureus       Date:  2022-08-21

8.  Factors predicting final visual outcome in quiescent proliferative diabetic retinopathy.

Authors:  Jinsoo Kim; In Won Park; Soonil Kwon
Journal:  Sci Rep       Date:  2020-10-14       Impact factor: 4.379

9.  Clinical effect of conbercept on improving diabetic macular ischemia by OCT angiography.

Authors:  Ziyi Zhu; Youling Liang; Bin Yan; Zhishang Meng; Kejun Long; Yiwei Zhang; Jing Luo
Journal:  BMC Ophthalmol       Date:  2020-09-25       Impact factor: 2.209

10.  Factors Influencing Response to Aflibercept in Diabetic Macular Oedema Patients in a Diverse North West London Population: A Real-World Study.

Authors:  Sing Yue Sim; Arevik Ghulakhszian; Amal Minocha; Dhannie Ramcharan; Soroush Nokhostin; Richard Cheong-Leen; Sheena George; Esther Posner; Christiana Dinah
Journal:  Clin Ophthalmol       Date:  2021-05-20
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.